Breaking News
Get 50% Off 0
50% Off! Beat the market in 2025 with InvestingPro
CLAIM SALE
Close

Pictet-biotech Hp Chf (0P0000X7XY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
622.700 +0.670    +0.11%
23/12 - Closed. Currency in CHF
Type:  Fund
Market:  Luxembourg
ISIN:  LU0843168732 
Asset Class:  Equity
  • Morningstar Rating:
  • Total Assets: 1.35B
Pictet Biotech HP CHF 622.700 +0.670 +0.11%

0P0000X7XY Historical Data

 
Get free historical data for 0P0000X7XY fund. You'll find the end of day price of the Pictet-biotech Hp Chf fund for the selected range of dates. The data can be viewed in daily, weekly or monthly time intervals. At the bottom of the table you'll find the data summary for the selected range of dates.
Time Frame:
11/25/2024 - 12/25/2024
 
Date Price Open High Low Change %
Dec 23, 2024 622.700 622.700 622.700 622.700 0.11%
Dec 20, 2024 622.030 622.030 622.030 622.030 1.05%
Dec 19, 2024 615.560 615.560 615.560 615.560 -5.60%
Dec 18, 2024 652.100 652.100 652.100 652.100 -0.16%
Dec 17, 2024 653.160 653.160 653.160 653.160 0.26%
Dec 16, 2024 651.470 651.470 651.470 651.470 1.47%
Dec 13, 2024 642.040 642.040 642.040 642.040 -2.53%
Dec 12, 2024 658.730 658.730 658.730 658.730 -0.99%
Dec 11, 2024 665.290 665.290 665.290 665.290 -0.79%
Dec 10, 2024 670.590 670.590 670.590 670.590 -1.01%
Dec 09, 2024 677.410 677.410 677.410 677.410 0.66%
Dec 06, 2024 672.980 672.980 672.980 672.980 -0.11%
Dec 05, 2024 673.720 673.720 673.720 673.720 0.35%
Dec 04, 2024 671.390 671.390 671.390 671.390 -0.67%
Dec 03, 2024 675.900 675.900 675.900 675.900 -0.35%
Dec 02, 2024 678.300 678.300 678.300 678.300 -0.94%
Nov 29, 2024 684.710 684.710 684.710 684.710 0.60%
Nov 27, 2024 680.610 680.610 680.610 680.610 1.41%
Nov 26, 2024 671.150 671.150 671.150 671.150 -0.98%
Nov 25, 2024 677.820 677.820 677.820 677.820 2.06%
Highest: 684.710 Lowest: 615.560 Difference: 69.150 Average: 660.883 Change %: -6.235
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

0P0000X7XY Comments

Write your thoughts about Pictet-biotech Hp Chf
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email